Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks

Genmab (GMAB) has received a new Hold rating, initiated by Morgan Stanley analyst, Judah Frommer.

Judah Frommer has given his Hold rating due to a combination of factors related to Genmab’s evolving risk‑reward profile after the Merus acquisition. He sees the shift from a royalty-heavy model toward a fully integrated biotech, anchored by petosemtamab and Epkinly, as strategically attractive but still in the early innings of execution, warranting a balanced stance at this stage.

Frommer’s $34 price target, only modestly above the current share price, reflects that much of the near‑term upside hinges on pivotal data expected in 2026 across head and neck cancer, DLBCL, and ovarian cancer. While he acknowledges meaningful optionality in a bullish scenario, particularly if peak market share for petosemtamab and Epkinly exceeds assumptions, he also recognizes clinical, competitive, and commercialization risks that keep the risk‑adjusted valuation aligned with an Equal‑weight recommendation rather than a more aggressive rating.

Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, Incyte, and PTC Therapeutics. According to TipRanks, Frommer has an average return of -0.4% and a 50.99% success rate on recommended stocks.